Skip to main content
Fig. 3 | Biomarker Research

Fig. 3

From: Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling

Fig. 3

Crizotinib exhibited greater sensitivity towards Ba/F3-CD74-ROS1 cells compared to Ba/F3-WT cells, and its efficacy was enhanced when combined with IN10018. A, B Dose–response curves for the proliferation of Ba/F3-WT and Ba/F3-CD74-ROS1 cells treated with crizotinib for 48 h and 72 h, respectively. C, D Dose–response curves for the proliferation of Ba/F3-WT and Ba/F3-CD74-ROS1 cells treated with IN10018 for 48 h and 72 h, respectively. E, F The cell viability of IN10018 and crizotinib in Ba/F3-WT cells. The concentration ratio of IN10018 and Crizotinib is 2:1. G, H The CI value of Ba/F3-WT cells treated with IN10018, crizotinib, or combination therapy. I, J The cell viability of IN10018 and crizotinib in Ba/F3-CD74-ROS1 cells. The concentration ratio of IN10018 and Crizotinib is 2:1. K, L The CI value of Ba/F3-CD74-ROS1 cells treated with IN10018, crizotinib, or combination therapy. Significant levels: ns = not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us